<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079911</url>
  </required_header>
  <id_info>
    <org_study_id>100181</org_study_id>
    <nct_id>NCT00079911</nct_id>
  </id_info>
  <brief_title>A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons</brief_title>
  <official_title>An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons With CD4+ Lymphocyte Count &lt;100 Cells/mm3.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical research study will be an international trial evaluating the safety and&#xD;
      effectiveness of a marketed drug compared to placebo (like a sugar pill) for the suppression&#xD;
      of repeated genital herpes infections in HIV-infected subjects with CD4+ count &lt;100&#xD;
      cells/mm3.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated&#xD;
  </why_stopped>
  <start_date type="Actual">March 12, 2004</start_date>
  <completion_date type="Actual">October 15, 2004</completion_date>
  <primary_completion_date type="Actual">October 15, 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The nature and incidence of adverse events, by treatment group, reported during the 6-month study will be summarized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of recurrence of genital HSV</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Secondary outcome measures are the proportion of subjects recurrence-free of genital HSV at 6 months, and the time to first culture-positive recurrence of genital HSV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first culture-positive recurrence of genital HSV</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Secondary outcome measures are the proportion of subjects recurrence-free of genital HSV at 6 months, and the time to first culture-positive recurrence of genital HSV.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Herpes Genitalis</condition>
  <arm_group>
    <arm_group_label>Suppressive + Episodic Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valaciclovir (VAL) 500mg twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 days or 10 days, when required for treatment of a genital herpes recurrence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Episodic Therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 or 10 days, when required for treatment of a genital herpes recurrence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valacyclovir hydrochloride</intervention_name>
    <description>valacyclovir hydrochloride</description>
    <arm_group_label>Episodic Therapy</arm_group_label>
    <arm_group_label>Suppressive + Episodic Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CD4+ lymphocyte count &lt;100cells/mm3 at the screening visit.&#xD;
&#xD;
          -  Documented history of HIV infections&#xD;
&#xD;
          -  Must have received stable, combination anti HIV drugs for at least 4 months&#xD;
             immediately prior to participation, and per the investigator, are unlikely to require&#xD;
             change in anti-HIV drugs during the six-month study.&#xD;
&#xD;
          -  Laboratory confirmation of genital herpes (a positive Herpes Simplex Virus-2 antibody&#xD;
             test).&#xD;
&#xD;
          -  3 or more outbreaks of genital herpes in the previous 12 months if not on genital&#xD;
             herpes medicines currently.&#xD;
&#xD;
          -  3 or more outbreaks of genital herpes per year in the period prior to beginning of&#xD;
             treatment for chronic genital herpes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Kidney diseases.&#xD;
&#xD;
          -  Liver diseases.&#xD;
&#xD;
          -  Known allergic reactions to VALTREX (valaciclovir), ZOVIRAX (acyclovir), FAMVIR&#xD;
             (famciclovir), or CYTOVENE (ganciclovir).&#xD;
&#xD;
          -  Vomiting syndrome.&#xD;
&#xD;
          -  Must be willing to discontinue taking current genital herpes medicines 1 week prior to&#xD;
             participation.&#xD;
&#xD;
          -  Active AIDS-indicator conditions, as defined by CDC Category C.&#xD;
&#xD;
          -  Other protocol inclusion and exclusion criteria to be evaluated by the research&#xD;
             physician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kowloon Bay</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hong Kong</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 18, 2004</study_first_submitted>
  <study_first_submitted_qc>March 18, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2004</study_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Herpes</keyword>
  <keyword>Genital Herpes</keyword>
  <keyword>HIV</keyword>
  <keyword>HSV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Genitalis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

